| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8778438 | European Urology | 2018 | 11 Pages |
Abstract
Bacillus Calmette-Guérin (BCG) immunotherapy is an effective treatment for many patients with nonmuscle invasive bladder cancer. An individual's response to BCG can be predicted by using various features of the cancer. In the future, predictive markers using molecular measures of the tumor type and the immune response to BCG may allow us to precisely know an individual's likely outcome after BCG treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Ashish M. Kamat, Roger Li, Michael A. O'Donnell, Peter C. Black, Morgan Roupret, James W. Catto, Eva Comperat, Molly A. Ingersoll, Wim P. Witjes, David J. McConkey, J. Alfred Witjes,